Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage
Miller was given 4M Preferred “B” for .25 value or $1M
He bought back his Company’s for $1M giving back the Prefferds B
Them did go to BioHydro and again returned and used for Hans’s Dazed, Inc or which is now Wyoming Registered with an Name change already done and filed for New $Ticker
Hopefully $DAZE — JMO
No ownership claimed anymore —>
"+coffeeshop"
The updated Lazydaze #branding. Small changes= big impact!! $medh
The updated Lazydaze #branding. Small changes= big impact!! $medh https://t.co/8SFvttfQkH
— Dazed Inc. (@DazedBrands) July 15, 2022
Lazydaze Vibes — $DAZE
It's official! We are now Dazed Inc.
https://mobile.twitter.com/The1OnlyHans/with_replies
JMO - Gonna MoveUp from Here
Outstanding: 1,674,868 on July 11, 2022
Monthly 5th Report
https://webfiles.thecse.com/6._Algernon_-_CSE_Form_7_-_June.pdf?N4gFK.usdmkRERcVdNfEs84PtSs8U6XZ
Can the Psychedelic Drug DMT Take Algernon to the Next Level?
https://www.streetwisereports.com/article/2022/07/11/pharma-looks-to-improve-potential-psychedelic-stroke-drug.html
$BLOZF Participates in New Study with Marijuana Breathalyzer technology – Southern United States
https://ih.advfn.com/stock-market/USOTC/cannabix-technologies-pk-BLOZF/stock-news/88573992/cannabix-technologies-participates-in-new-study-wi
Outstanding: 114,144,104 for July 5, 2022
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_July_5_2022.pdf?tho3Iw52fvejKbP2fAak5nLJqlucrKdm
Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Provides-Update-on-its-Planned-Phase-1-Repirinast-Chronic-Kidney-Disease-Study?id=364219
Looks like they fixed your claim - But granted you were correct at the time using Wyoming Secretary of State when OTC already posted with Attorneys letter to boot
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168860405
07/06/2022 Wyoming Secretary of State posted Current
https://wyobiz.wyo.gov/Business/FilingDetails.aspx?eFNum=095005198060174083219081253009120205228211135226
Even list Hans as President
Look at this - Current with Wyoming 07/06/2022
Name change is happening I’d say — JMO
Proactive Investors Interview - Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September of 2022
Update on Its Phase 1 DMT Stroke Study
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Provides-Update-on-Its-Phase-1-DMT-Stroke-Study?id=363918
Outstanding Shares 690,499,016 posted 07/01/2022
https://www.otcmarkets.com/stock/MEDH/security
Follow @DazedCorp for @lazydazeco & $medh updates.
8:25 AM · Jul 4, 2022
Follow @DazedCorp for @lazydazeco & $medh updates.
— the 1 & Only HANS (@The1OnlyHans) July 4, 2022
JMO —
Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Discloses-Novel-DMT-Salt-Patent-Strategy-Includes-Bioactive-Nicotinate-and-Pamoate?id=363557
Outstanding Shares 261,666,851 posted 07/01/2022
https://www.otcmarkets.com/stock/CNNA/security
$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE
$DAZE or $VERD ?
Of corse it would be
$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $DAZE $$DAZE $DAZE
For Me
Whatcha think for the ticker change to DAZE or VERD from $medh ? Note: we are going all in on consumption lounges
https://mobile.twitter.com/The1OnlyHans
DATE: 06/15/2022 SHORT INTEREST: 5
https://www.otcmarkets.com/stock/MEDH/quote#trade-data
Roberto von Muller
Company
Verdosa Holdings Inc.
Name
Roberto von Muller
Address
5330 Manchaca Rd. Ste. A, Austin, TX, 78745, USA
Position
director
https://opencorporates.com/officers/536965364
Now here’s Verdosa Farms LLC and Hans not on it but Roberto von Muller is and I believe $MEDH will acquire at some point if not already - Dates of both becoming a Company is just a few days apart
https://opencorporates.com/companies/us_tx/0804121123
Take yourself for a ride - JMO
https://verdosa.com/
Time to make moves! $medh
@DazedCorp
https://mobile.twitter.com/search?q=%24medh&src=cashtag_click&f=live
L2 this Week has Couple More Traders joining here
Pricing of Public Offering of Units
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Pricing-of-Public-Offering-of-Units?id=362616
Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Issuance-of-Patent-for-Ifenprodil-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis?id=362124
VANCOUVER, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the Canadian Intellectual Property Office (“CIPO”), No. 3101853, for the treatment of interstitial lung disease with NP-120 (“Ifenprodil”), entitled “Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis.”
The invention claims treating interstitial lung disease, including idiopathic pulmonary fibrosis (“IPF”), with Ifenprodil. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company also has active patent applications for Ifenprodil for the same compositions and methods in the U.S., Europe, China and Japan.
Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications covering method of use for new disease indications, as well as dosing and formulation. In addition, the Company has filed new composition of matter patents for novel salt forms for some of its lead compounds.
“We are very pleased to be granted this patent by the CIPO,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “This is an important milestone for the Company as we continue to strengthen our global IP position.”
About Ifenprodil
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils and certain types of cancer cells.
The Company is conducting a proof-of-concept Phase 2 human trial to determine the safety and efficacy of Ifenprodil in patients with IPF and its associated cough and recently announced it had reached database lock.
Topline data from this study is expected in July 2022.
Don’t forget the Filings
Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE)
Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, announces that patients from multiple sites participating in its Phase 2 proof of concept study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough, being conducted in Australia and New Zealand, have requested ongoing supply of Ifenprodil for their personal use beyond the study’s treatment period. The company is helping the clinical sites obtain additional supply of the drug through the Australian Government’s Special Access Scheme; a mechanism which allows patients to access unapproved therapeutic goods.
As previously stated, the Company is projecting that topline data from the Phase 2 study will be available in July 2022.
The Company is advising that it is not making any express or implied claims that Ifenprodil has the ability to cure or treat IPF or chronic cough at this time.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed intellectual property rights globally for Ifenprodil for the treatment of respiratory diseases.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
BLLB Merges With Youth Sports & Recreation Leader Jump Start Sports
https://www.otcmarkets.com/stock/BLLB/news/Bell-Buckle-Holdings-Merges-With-Youth-Sports--Recreation-Leader-Jump-Start-Sports?id=361949
“yeah what else to the story have I missed? I'd love to read others original thoughts.”
I could let you have @ this Angle of Thought
https://mailchi.mp/psychedelicfinance/june17-10135980?e=e795a0a94d
That Link above is “Psychedelic Finance” and list all Psychedelic stocks and there now (2) ETF’s on Psychedelic and coming soon is another I heard
Question is, the Dr that Kal had for NASH Pharma still @ work??
Nasdaq Stocks and Psychedelic ETF’s would be probably a Winner for pushing share price
As for Nasdaq — My Thought — Algernon Needs way more Cash to be there and going elsewhere to Raise the Cash needed for Nasdaq — JMO — Cash being Raised will only be enough to do a few of what their chasing
Bottom line on me — They said they were Approved Nasdaq @ $4.11 USA dollar and Stock was sitting $3
(25% uptick was a good Buy if one bought)
Watch out for the Shorts after the run like that
JMO — A run and a fake Short after a Big 50% or 100% run will be a Buy — Kal’s got the Cash threw others to Push this much Higher when ready — JMO
Here’s one I like and those in the Heat Wave - Hopefully you can feel the Chill - Happy Father’s Day Coming Soon
Is that a Knock knock joke?
“Knock knock, I'm home, and coherent man...”
Knock knock, I'm home, and coherent man...Who?
Knock knock, I'm home and coherently after Smoking Weed and sipping Coffee @ a LazyDaze CounterCulture Shop Coming near you Someday
Love this Post from CEO Hans
Franchising interest in picking up again & we will be launching a SMART marketing campaign over the summer. This will increase lead gen & data collection. We're seeking expereinced developers & partners, not mom & pop buyers. GOAL:
— the 1 & Only HANS (@The1OnlyHans) May 29, 2022
36 corp stores & 36 frans in 3 years.#franchise
Hopefully OTC will update our status $medh to Pink Current soon. That would be great everyone! and I very much would like to change the name asap. @VerdosaHoldings $verd . Still need to wait on a few legal formalities to occur, but rest assured it will happen. #Focus
— the 1 & Only HANS (@The1OnlyHans) May 29, 2022
You get their email yesterday of a Placement which is not to be able to Trade USA and if bought it’s labeled “Restricted Share count”
Cann American Corp. Announces Hemp Farming Lease
https://www.otcmarkets.com/stock/CNNA/news/Cann-American-Corp-Announces-Hemp-Farming-Lease?id=361445
It’s Dated April 27, 2022 also but is also the same one listed on CSE site and was Filed 04/27/2022 there
Maybe $AGNP is coming soon is why the late Filing on the OTC site — Have you noticed that the Nasdaq Listing is kinda hid from those using CSE only site? At least I have a hard time finding anything about trying for a Nasdaq listing
https://webfiles.thecse.com/AlgernonFeb2822MDA.pdf?MAKhYuiJrGBk8E.AiftdxmG.7z1MBhuO
https://www.otcmarkets.com/otcapi/company/financial-report/337180/content
Management Discussion and Analysis
https://www.otcmarkets.com/otcapi/company/financial-report/337180/content
Condensed Interim Consolidated Financial Statements
https://www.otcmarkets.com/otcapi/company/financial-report/337179/content
Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Database-Lock-in-Phase-2-Study-of-IPF-and-Chronic-Cough?id=360894
Outstanding: 1,674,868 on June 7, 2022
Monthly 5th Report
https://webfiles.thecse.com/5._Algernon_-_CSE_Form_7_-_May.pdf?e4OhHq9hZhO3NgVaBr5QfJ90Mxd5EzNx